← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,234	+28	+1%	$221B
2	2 Pfizer PFE $166B	1,993	+24	+1%	$152B
3	3 Merck MRK $364B	1,762	+17	+1%	$118B
4	4 AbbVie ABBV $501B	1,636	-4	-0.2%	$69.8B
5	5 Gilead Sciences GILD $190B	1,599	-33	-2%	$86.8B
6	6 Bristol-Myers Squibb BMY $121B	1,577	+53	+3%	$90.7B
7	7 Amgen AMGN $230B	1,474	+38	+3%	$91.2B
8	8 Novartis NVS $279B	879	+3	+0.3%	$19.4B
9	9 GSK GSK $95.9B	742	+15	+2%	$9.37B
10	10 Regeneron Pharmaceuticals REGN $80.1B	542	-8	-1%	$25.3B
11	11 AstraZeneca AZN $251B	398	+8	+2%	$8.72B
12	12 Incyte INCY $22.6B	371	+12	+3%	$14B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	367	+27	+8%	$11.2B
14	14 Myriad Genetics MYGN $397M	253	+19	+8%	$2.5B
15	15 Opko Health OPK $1.02B	245	-14	-5%	$1.08B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	214	+20	+10%	$5.6B
17	17 DELISTED Assertio ASRT	207	+11	+6%	$1.28B
18	18 DELISTED Exact Sciences EXAS	181	+14	+8%	$1.18B
19	19 Precigen PGEN $2.64B	169	-22	-12%	$2.45B
20	20 Exelixis EXEL $15.1B	166	+22	+15%	$1.48B
21	21 Halozyme HALO $13.3B	161	0	0%	$907M
22	SPPI 22 DELISTED Spectrum Pharmaceuticals Inc SPPI	161	+30	+23%	$362M
23	23 DELISTED Immunogen Inc IMGN	158	+15	+10%	$251M
24	24 NeoGenomics NEO $2.17B	155	+36	+30%	$483M
25	25 Kyntra Bio KYNB $22.6M	146	+12	+9%	$518M